Fairfield, Bush & Co’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.95M Sell
19,344
-2,269
-10% -$348K 1.64% 15
2025
Q4
$2.98M Sell
21,613
-1,241
-5% -$163K 1.57% 15
2025
Q3
$2.93M Sell
22,854
-1,370
-6% -$167K 1.5% 17
2025
Q2
$2.93M Sell
24,224
-828
-3% -$93.3K 1.66% 15
2025
Q1
$2.79M Sell
25,052
-464
-2% -$49.4K 1.77% 14
2024
Q4
$2.48M Buy
25,516
+567
+2% +$60.5K 1.46% 17
2024
Q3
$2.87M Sell
24,949
-3,668
-13% -$416K 1.71% 15
2024
Q2
$3.05M Sell
28,617
-192
-0.7% -$19.3K 1.83% 13
2024
Q1
$2.79M Sell
28,809
-603
-2% -$61.8K 1.65% 16
2023
Q4
$2.97M Sell
29,412
-3,924
-12% -$379K 1.74% 13
2023
Q3
$3.4M Sell
33,336
-7,500
-18% -$761K 2.22% 11
2023
Q2
$4.12M Sell
40,836
-375
-0.9% -$37.5K 1.13% 20
2023
Q1
$3.79M Buy
41,211
+7,461
+22% +$652K 1.34% 20
2022
Q4
$3.06M Sell
33,750
-292
-0.9% -$24.6K 2.02% 14
2022
Q3
$2.59M Sell
34,042
-3,103
-8% -$257K 1.83% 16
2022
Q2
$3.14M Sell
37,145
-4,478
-11% -$393K 1.85% 16
2022
Q1
$3.65M Buy
41,623
+58
+0.1% +$5.02K 1.83% 15
2021
Q4
$3.64M Sell
41,565
-11,525
-22% -$957K 1.75% 16
2021
Q3
$4.34M Sell
53,090
-8,804
-14% -$792K 1.41% 15
2021
Q2
$5.65M Sell
61,894
-3,109
-5% -$277K 1.53% 17
2021
Q1
$5.56M Sell
65,003
-610
-0.9% -$54.7K 1.59% 13
2020
Q4
$6.2M Hold
65,613
1.81% 11
2020
Q3
$5.71M Sell
65,613
-40
-0.1% -$3.46K 1.82% 12
2020
Q2
$5.73M Sell
65,653
-79
-0.1% -$6.82K 2.05% 11
2020
Q1
$5.42M Sell
65,732
-1,688
-3% -$151K 2.25% 10
2019
Q4
$6.38M Sell
67,420
-699
-1% -$62.7K 2.35% 10
2019
Q3
$5.92M Sell
68,119
-2,962
-4% -$266K 2.05% 12
2019
Q2
$6.49M Sell
71,081
-16,138
-19% -$1.37M 2.21% 11
2019
Q1
$7.51M Sell
87,219
-1,102
-1% -$88.5K 2.49% 10
2018
Q4
$6.79M Sell
88,321
-553
-0.6% -$43K 2.34% 11
2018
Q3
$6.86M Sell
88,874
-9,322
-9% -$689K 1.93% 13
2018
Q2
$6.65M Sell
98,196
-5,018
-5% -$346K 1.95% 15
2018
Q1
$7.48M Sell
103,214
-8,043
-7% -$612K 2.17% 13
2017
Q4
$8.37M Buy
111,257
+5,486
+5% +$414K 2.31% 13
2017
Q3
$8.14M Sell
105,771
-39
-0% -$2.94K 2.54% 10
2017
Q2
$7.91M Buy
105,810
+123
+0.1% +$8.72K 2.54% 11
2017
Q1
$7.03M Sell
105,687
-977
-0.9% -$65.1K 2.19% 16
2016
Q4
$6.96M Sell
106,664
-2,288
-2% -$148K 2.26% 14
2016
Q3
$7.71M Sell
108,952
-1,081
-1% -$78.8K 2.5% 12
2016
Q2
$8.13M Sell
110,033
-2,057
-2% -$142K 2.82% 10
2016
Q1
$7.28M Buy
112,090
+58,506
+109% +$3.98M 2.6% 12
2015
Q4
$4.13M Buy
53,584
+5,162
+11% +$410K 1.45% 28
2015
Q3
$3.99M Sell
48,422
-19,199
-28% -$1.71M 1.75% 20
2015
Q2
$5.96M Sell
67,621
-341
-0.5% -$31.3K 1.79% 16
2015
Q1
$6M Sell
67,962
-899
-1% -$79.7K 1.75% 15
2014
Q4
$5.72M Sell
68,861
-418
-0.6% -$34.6K 1.64% 18
2014
Q3
$5.84M Sell
69,279
-959
-1% -$77.6K 1.68% 18
2014
Q2
$5.7M Buy
70,238
+4,771
+7% +$375K 1.67% 18
2014
Q1
$4.99M Sell
65,467
-28
-0% -$2.04K 2.35% 15
2013
Q4
$4.72M Sell
65,495
-12,964
-17% -$901K 2.11% 21
2013
Q3
$5.39M Buy
78,459
+69,682
+794% +$4.61M 1.63% 21
2013
Q2
$556K Buy
+8,777
New +$571K 0.28% 85

Other funds holding NVS

Fairfield, Bush & Co's NVS Position: Q1 2026 in Review

Fairfield, Bush & Co reduced its Novartis (NVS) stake by 10% in Q1 2026, selling an estimated $348K and leaving 19,344 shares worth $2.95M. The position accounts for 1.64% of the portfolio, ranked #15.

Fairfield, Bush & Co first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. The position peaked at $8.37M in Q4 2017. 1,592 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Fairfield, Bush & Co held 19,344 shares of Novartis worth $2.95M as of Q1 2026.
  • Fairfield, Bush & Co sold 2,269 Novartis shares in Q1 2026, an estimated $348K.
  • Novartis made up 1.64% of Fairfield, Bush & Co's portfolio in Q1 2026, its #15 holding.
  • Fairfield, Bush & Co first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
  • Fairfield, Bush & Co's Novartis position peaked at $8.37M in Q4 2017.
  • 1,592 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Fairfield, Bush & Co's 13F filing for Q1 2026, filed 12 May 2026.